1-20 of 34
Alan Huang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3242: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors

Alvin Lu, Brian Haines, Ji Lei, Wenhai Zhang, Minjie Zhang, Douglas A. Whittington, Maria Lucia Ferdinez, Yi Yu, Samuel R. Meier, Ashley Choi, Alborz Bejnood, Madhavi Bandi, Katherine Lazarides, Xuewen Pan, Lina Gu, Alice W. Tsai, Sirimas Sudsakorn, Colin Liang, Jon Come, Brett Williams, Scott Throner, Joseph Vacca, John P. Maxwell, Jannik N. Anderson, Alan Huang, Chengyin Min, Yingnan P. Chen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3242.
https://doi.org/10.1158/1538-7445.AM2024-3242
Published: 22 March 2024
View article titled, Abstract 3242: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors
Journal Articles

Abstract 3363: LIG1 inactivation selectively inhibits growth of BRCA1 mutant cells in vitro and in vivo

Lauren Martires, Leanne G. Ahronian, Charlotte Pratt, Nikitha Das, Xiaobin Zhang, Douglas A. Whittington, Hongxiang Zhang, Binzhang Shen, Jon Come, Patrick McCarren, Mu-Sen Liu, Chengyin Min, Tianshu Feng, Haris Jahic, Eric Brophy, Daniel Aird, Jannik N. Andersen, Alan Huang, Fang Li, William D. Mallender, Hilary E. Nicholson
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3363.
https://doi.org/10.1158/1538-7445.AM2024-3363
Published: 22 March 2024
View article titled, Abstract 3363: LIG1 inactivation selectively inhibits growth of BRCA1 mutant cells in vitro and in vivo
Journal Articles

Abstract ND12: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers

Leanne G. Ahronian, Minjie Zhang, Chengyin Min, Alice W. Tsai, Jacques Ermolieff, Patrick McCarren, Margaret Wyman, David Guerin, Ye Wang, Alborz Bejnood, Kenjie Amemiya, Brian McMillan, Nikitha Das, Preksha Shahagadkar, Brian Doyon, Andre Mignault, Colin Liang, Vassil Elitzin, Samuel R. Meier, Ashley Choi, Yi Yu, John P. Maxwell, Brian B. Haines, Jannik N. Andersen, Heather DiBenedetto, Aaron Weitzman, Alan Huang, Xinyuan Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): ND12.
https://doi.org/10.1158/1538-7445.AM2023-ND12
Published: 29 May 2023
View article titled, Abstract ND12: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers
Journal Articles

Abstract 4970: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors

Kimberly J. Briggs, Alice Tsai, Minjie Zhang, Matthew R. Tonini, Brian Haines, Alan Huang, Kevin M. Cottrell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4970.
https://doi.org/10.1158/1538-7445.AM2023-4970
Published: 04 April 2023
View article titled, Abstract 4970: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors
Journal Articles

Abstract 4968: Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers

Antoine Simoneau, Hsin-Jung Wu, Madhavi Bandi, Katherine Lazarides, Sining Sun, Shangtao Liu, Samuel Meier, Ashley Choi, Hongxiang Zhang, Binzhang Shen, Douglas Whittington, Sirimas Sudsakorn, Wenhai Zhang, Yi Yu, Yong Liu, Colin Liang, Michael Palmieri, Yingnan Chen, Brian Haines, Alice Tsai, Minjie Zhang, Alan Huang, Jannik Andersen, Tianshu Feng, Scott Throner, John Maxwell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4968.
https://doi.org/10.1158/1538-7445.AM2023-4968
Published: 04 April 2023
View article titled, Abstract 4968: Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers
Journal Articles

Abstract 3452: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models

Minjie Zhang, Alice Tsai, Kevin M. Cottrell, Brian B. Haines, Erik Wilker, Heather DiBenedetto, Ron Weitzman, Alan Huang, Charles B. Davis, John P. Maxwell, Kimberly J. Briggs
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3452.
https://doi.org/10.1158/1538-7445.AM2023-3452
Published: 04 April 2023
View article titled, Abstract 3452: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models
Journal Articles

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Julie A. Shields, Samuel R. Meier, Madhavi Bandi, Erin E. Mulkearns-Hubert, Nicole Hajdari, Maria Dam Ferdinez, Justin L. Engel, Daniel J. Silver, Binzhang Shen, Wenhai Zhang, Christopher G. Hubert, Kelly Mitchell, Sajina Shakya, Shan-Chuan Zhao, Alborz Bejnood, Minjie Zhang, Robert Tjin Tham Sjin, Erik Wilker, Justin D. Lathia, Jannik N. Andersen, Yingnan Chen, Fang Li, Barbara Weber, Alan Huang, Natasha Emmanuel
Journal: Cancer Research
Cancer Res (2022) 82 (21): 4044–4057.
https://doi.org/10.1158/0008-5472.CAN-21-4443
Published: 02 November 2022
View article titled, VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
Open the PDF for VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2603: USP1 inhibitor synthetic lethality in BRCA1-mutant cancer is driven by PCNA ubiquitination

Justin Engel, Madhavi Bandi, Antione Simoneau, Katherine Lazarides, Deepali Gotur, Truc Pham, Shangtao Liu, Samuel Meier, Ashley Choi, Hongxiang Zhang, Binzhang Shen, Fang Li, Douglas Whittington, Shanzhong Gong, Xuewen Pan, Yi Yu, Lina Gu, Scott Throner, John Maxwell, Yingnan Chen, Alan Huang, Jannik Andersen, Tianshu Feng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2603.
https://doi.org/10.1158/1538-7445.AM2022-2603
Published: 15 June 2022
View article titled, Abstract 2603: USP1 inhibitor synthetic lethality in BRCA1-mutant cancer is driven by PCNA ubiquitination
Journal Articles

Abstract 3941: TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies

Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Erik W. Wilker, Lina Gu, Charles B. Davis, Minjie Zhang, Doug Whittington, Deepali Gotur, Matthew J. Goldstein, Heather DiBenedetto, Marc S. Rudoltz, Alan Huang, John P. Maxwell
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3941.
https://doi.org/10.1158/1538-7445.AM2022-3941
Published: 15 June 2022
View article titled, Abstract 3941: TNG908 is an MTAP<sup>null</sup>-selective PRMT5 inhibitor that drives tumor regressions in <em>MTAP</em>-deleted xenograft models across multiple histologies
Journal Articles

Abstract 1224: UMIBB: A novel nonparametric Bayesian method improves robustness and sensitivity of analysis in pooled CRISPR-Cas9 screens leveraging unique molecular identifiers

Ashley Choi, Samuel Meier, Silvia Fenoglio, Tianshu Feng, Justin Engel, Binzhang Shen, Shangtao Liu, Teng Teng, Tenzing Khendu, Alan Huang, Jannik Andersen, Xuewen Pan, Yi Yu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1224.
https://doi.org/10.1158/1538-7445.AM2022-1224
Published: 15 June 2022
View article titled, Abstract 1224: UMIBB: A novel nonparametric Bayesian method improves robustness and sensitivity of analysis in pooled CRISPR-Cas9 screens leveraging unique molecular identifiers
Journal Articles

Abstract 1905: In vivo CRISPR screen identifies tumor suppressors as drivers of tumor cell-intrinsic immune evasion

Chengyin Min, Ferdinandos Skoulidis, Wenrong Zhou, Jennifer Tsoi, Alan Huang, Matthew J. Goldstein
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1905.
https://doi.org/10.1158/1538-7445.AM2021-1905
Published: 01 July 2021
View article titled, Abstract 1905: <em>In vivo</em> CRISPR screen identifies tumor suppressors as drivers of tumor cell-intrinsic immune evasion
Journal Articles

Abstract 406: Profiling plasma cell-free RNA (cfRNA) with the NanoString low input nCounter assay

Chung-Ying (Alan) Huang, Sarah Warren, Jason Reeves, Megan Wurden, Tim Riordan, Rich Boykin, Mingdong Liu, David Henderson, Dan Hanson, Jay Gerlach, Joseph M. Beechem
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 406.
https://doi.org/10.1158/1538-7445.AM2019-406
Published: 01 July 2019
View article titled, Abstract 406: Profiling plasma cell-free RNA (cfRNA) with the NanoString low input nCounter assay
Journal Articles

Abstract LB-015: Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody

Jianqun Kou, Ben Staal, Phillip R. Musich, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Tam Angela, Alan Huang, Huaixiang Hao, George F. Vande Woude, Qian Xie
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-015.
https://doi.org/10.1158/1538-7445.AM2018-LB-015
Published: 01 July 2018
View article titled, Abstract LB-015: Differential therapeutic responses of MET oncogenic activations to Met kinase inhibitor and neutralizing antibody
Journal Articles

Abstract 2892: EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer

Kimberly J. Briggs, Chengyin Min, Hongxiang Zhang, Alan Huang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2892.
https://doi.org/10.1158/1538-7445.AM2018-2892
Published: 01 July 2018
View article titled, Abstract 2892: EGLN1 is a synthetic lethal target in <em>ARID1A</em>-mutant ovarian cancer
Journal Articles

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Gino B. Ferraro, David P. Kodack, Vasileios Askoxylakis, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Alexander Z. Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Youngchul Song, Carlotta Costa, Kamila Naxerova, Christina Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, Ryan C. Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Valeria M. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5008.
https://doi.org/10.1158/1538-7445.AM2017-5008
Published: 01 July 2017
View article titled, Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Journal Articles

Abstract 782: Modulation of receptor tyrosine kinase signaling by cMET inhibitor, INC280, in cMETmut/amp gastric carcinoma cell line Hs746.T

Maria C. Pinzon-Ortiz, Xianhui Rong, Jinsheng Liang, Hui Qin Wang, Alan Huang, Robert Schlegel, Z. Alexander Cao
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 782.
https://doi.org/10.1158/1538-7445.AM2015-782
Published: 01 August 2015
View article titled, Abstract 782: Modulation of receptor tyrosine kinase signaling by cMET inhibitor, INC280, in cMET<sup>mut/amp g</sup>astric carcinoma cell line Hs746.T
Journal Articles

Abstract C70: Integrative analysis of pharmacologic, genomic, and transcriptomic assays in cancer

Manway Liu, Anupama Reddy, Alan Huang, Giordano Caponigro, Joseph Lehar
Journal: Cancer Research
Cancer Res (2011) 71 (18_Supplement): C70.
https://doi.org/10.1158/1538-7445.FBCR11-C70
Published: 28 October 2014
View article titled, Abstract C70: Integrative analysis of pharmacologic, genomic, and transcriptomic assays in cancer
Journal Articles

Abstract 2929: The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models

Hui Qin Wang, Linda Battalagine, Jinsheng Liang, Ensar Halilovic, Robert Schlegel, Alan Huang, Z. Alexander Cao, John Monahan, Fang Li
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2929.
https://doi.org/10.1158/1538-7445.AM2014-2929
Published: 01 October 2014
View article titled, Abstract 2929: The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models
Journal Articles

Abstract 3683: Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

Z. Alexander Cao, Maria Pinzon-Ortiz, Yan Chen, Xiaoyan Li, Pedro J. Beltran, Jennifer Gansert, Malte Peters, Robert Schlegel, Karl M. Schumacher, Alan Huang
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3683.
https://doi.org/10.1158/1538-7445.AM2014-3683
Published: 01 October 2014
View article titled, Abstract 3683: Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab
Journal Articles

Abstract LB-237: Targeting HER3 and IGF1R in NRG1 high lung squamous cell carcinoma

Qing Sheng, Maria Pinzon-Ortiz, Rita Das, Alan Huang, Xianhui Rong, Z. Alexander Cao
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): LB-237.
https://doi.org/10.1158/1538-7445.AM2014-LB-237
Published: 01 October 2014
View article titled, Abstract LB-237: Targeting HER3 and IGF1R in NRG1 high lung squamous cell carcinoma